AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

LifeMax Appoints Kathy L Lampl, MD, as VP of Clinical Development

May 15, 2019

PALO ALTO, Calif.--(BUSINESS WIRE)--May 15, 2019--

LifeMax Laboratories, Inc. (“LifeMax”), a private company focused on treating rare diseases with few or no therapeutic options, today announced the appointment of Kathy L Lampl, MD, to the position of VP, Clinical Development. In this role, Dr. Lampl will be responsible for and provide strategic leadership to all aspects of clinical development for the entire pipeline. LifeMax has two clinical stage drug candidates in development. LM-030 has successfully completed a human proof of concept study for Netherton Syndrome, and LM-011 is currently in a human proof of concept study.

“We are very excited to welcome Dr. Kathy Lampl into our senior leadership. Dr. Lampl brings with her a wealth of experience in global clinical development across multiple therapeutic areas especially in the development of therapeutics for rare/ultra rare diseases. Her experience both in the industry and as a clinician serves very well with our goal of developing therapeutics for rare diseases with few or no treatment options,” said Larry Hsu, LifeMax’s Co-founder and CEO, an industry veteran who previously founded and built Impax Laboratories into a publicly traded multi-billion dollar company.

“I am very delighted to join the LifeMax management team. Well-funded and with a robust and diverse pipeline, LifeMax presents an exciting growth opportunity. I look forward to working with the team to bring much needed therapies to patients,” said Dr. Lampl.

Dr. Kathy Lampl comes to LifeMax from Ultragenyx where she was Senior Medical Director working on the global clinical development of products for rare/ultra rare diseases. Dr. Lampl was a practicing Allergist/Immunologist before building a successful career in the industry at companies including AstraZeneca and Genentech, in addition to Ultragenyx. Dr. Lampl received her medical degree from the University of Pennsylvania, did Internal Medicine residency at Rush University and fellowship in Clinical Immunology at Johns Hopkins. She is board certified in both Internal Medicine and Clinical Immunology.

About LifeMax Laboratories Inc.

LifeMax Laboratories, Inc. ( www.lifemaxlabs.com ), a wholly-owned subsidiary of LifeMax Healthcare International Corporation ( www.lifemaxhealthcare.com ), is a clinical-stage biotech company focused on treating rare diseases with few or no therapeutic options. LifeMax is applying its expertise and in-depth experience with drug development and commercialization to advance its well-balanced portfolio of products addressing critical unmet medical needs.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190515005007/en/

CONTACT: Media Contact

LifeMax Laboratories, Inc.

Laura Zhu, Ph.D., MBA

Email:laurazhu@lifemaxlabs.com

Tel: 650-285-6560 ext. 103

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL

SOURCE: LifeMax Laboratories, Inc.

Copyright Business Wire 2019.

PUB: 05/15/2019 07:00 AM/DISC: 05/15/2019 07:01 AM

http://www.businesswire.com/news/home/20190515005007/en